Lutathera
·
- Prescription status not stated
- Everything that fits nowhere else, such as contrast media
- Active substance
- Lutetium (177Lu) oxodotreotide
- Made by
- Novartis Europharm Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP?NETs) in adults.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Novartis Europharm Limited |
|---|---|
| Active substance | Lutetium (177Lu) oxodotreotide |
| Used in | Everything that fits nowhere else, such as contrast media |
| Classification | V10XX04 · Everything that fits nowhere else, such as contrast media |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Authorised on | 2017-09-26 |
| Last updated by the regulator | 2026-08-14 |
| EMA product number | EMEA/H/C/004123 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).